Giul, LLC v. Shenghuo Medical, LLC, D/B/A K2 Medical; Michael J. Antonoplos, Richard P. Blumberg, Mark L. Faupel, and Mark S. Pearlstein

CourtMassachusetts Supreme Judicial Court
DecidedAugust 28, 2024
Docket1984CV02862-BLS2
StatusPublished

This text of Giul, LLC v. Shenghuo Medical, LLC, D/B/A K2 Medical; Michael J. Antonoplos, Richard P. Blumberg, Mark L. Faupel, and Mark S. Pearlstein (Giul, LLC v. Shenghuo Medical, LLC, D/B/A K2 Medical; Michael J. Antonoplos, Richard P. Blumberg, Mark L. Faupel, and Mark S. Pearlstein) is published on Counsel Stack Legal Research, covering Massachusetts Supreme Judicial Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Giul, LLC v. Shenghuo Medical, LLC, D/B/A K2 Medical; Michael J. Antonoplos, Richard P. Blumberg, Mark L. Faupel, and Mark S. Pearlstein, (Mass. 2024).

Opinion

SUPREME JUDICIAL COURT

GIUL, LLC v. SHENGHUO MEDICAL, LLC, D/B/A K2 MEDICAL; MICHAEL J. ANTONOPLOS, RICHARD P. BLUMBERG, MARK L. FAUPEL, AND MARK S. PEARLSTEIN

Docket: 1984CV02862-BLS2
Dates: August 16, 2024
Present: Kenneth W. Salinger
County: SUFFOLK
Keywords: FINDINGS AND CONCLUSIONS AFTER A BENCH TRIAL

GIUL, LLC, contends that it was duped into making a bad investment in Shenghuo Medical, LLC, with the understanding that Shenghuo would use the money invested by GIUL to help fund Shenghuo’s own investment in Guided Therapeutics, Inc. (“GTI”). Some of GIUL’s claims were dismissed. Others were resolved in favor of defendants Shenghuo, Michael Antonoplos, Richard Blumberg, Mark Faupel, and Mark Pearlstein on summary judgment.

The Court recently tried GIUL’s remaining claims without a jury. Based on the findings below, the Court concludes that GIUL has failed to prove that it is entitled to any relief under the Massachusetts Uniform Securities Act (G.L. c. 110, § 410(a), known as “MUSA”) or under the Massachusetts Consumer Protection Act (G.L. c. 93A, § 11). GIUL did not prove its MUSA claim because it failed to show that any of the defendants offered or sold any security by making a false statement or by withholding material information. The MUSA claim against Faupel and Pearlstein also fails for the additional reasons that neither of them offered, sold, or transferred any security to GIUL; had control of Shenghuo; or materially aided the sale of securities to GIUL as an agent of Shenghuo. Finally, GIUL did not prove its c. 93A claim because it failed to prove that any of the defendants engaged in unfair or deceptive conduct in connection with GIUL’s investment in Shenghuo, either before GIUL made that investment or later on. Final judgment will therefore enter providing that GIUL shall take nothing on its claims.

1. Procedural Background. The following background explains the scope of the issues that the Court must now decide, and why the Court is deciding them without a jury.

                                                            -1-

1.1. Pre-trial Disposition of Certain Claims. Shenghuo’s original complaint asserted claims against Shenghuo, Antonoplos, Blumberg, Faupel, and Pearlstein. It also asserted reach-and-apply claims against Shenghuo and GTI.

The Court granted partial judgment on the pleadings, in August 2020, in favor of Mr. Pearlstein as to the claims against him for breach of fiduciary duty and to establish a constructive trust against his assets or property.

At the same time, the Court also denied GIUL’s motion to amend its complaint to assert substantive claims against GTI under MUSA and c. 93A. It concluded that these claims would be futile because GIUL’s proposed allegations did not plausibly suggest that GTI had control over Shenghuo or that any of the current defendants had actual or apparent authority to act as agents for GTI.

Fifteen months later, GIUL sought leave to file a different amended complaint. In March 2022, the Court permitted GIUL to add certain claims against existing defendants. But it denied the motion to the extent that GIUL sought to assert a claim for “fraud on the court” against the five current defendants, because there is no such thing as a cause of action for fraud on the court. The amended complaint that GIUL filed in accord with the Court’s March 2022 ruling is now the operative pleading.

The Court also denied GIUL’s request to add new claims against GTI for fraud, violation of G.L. c. 93A, and conspiracy to commit fraud. The Court concluded that the factual allegations in the proposed amended complaint did not plausibly suggest that GTI ever said or did anything to give Mark Faupel authority to serve as GTI’s agent in raising money from GIUL or others. GIUL twice sought interlocutory review of the Court’s second denial of leave to add claims against GTI. An Appeals Court single justice denied both petitions.

Judge Ricciuti granted summary judgment in favor of the Defendants in February 2023 on GIUL’s claims for fraud, breach of fiduciary duty, and breach of contract, as well as the two reach and apply claims. One year later, this Court (Salinger, J.) granted summary judgment in favor of the Defendants on GIUL’s claim for conspiracy, because there can be no civil conspiracy without an underlying common law tort and Judge Ricciuti had granted summary judgment in favor of the defendants on all of GIUL’s remaining tort claims.[1]

--------------------------------------------

[1]                    See Greene v. Philip Morris USA Inc., 491 Mass. 866, 871 (2023) (claim for concerted action civil conspiracy “is ‘akin to a theory of common law joint

<continued…>

                                                            -2-

1.2. Bench Trial of the MUSA and c. 93A Claims. This left only GIUL’s claims under MUSA and G.L. c. 93A to be tried. The Court ruled that GIUL had no right to a jury trial on either claim, and exercised its discretion to try these claims without a jury.

GIUL had no right to have a jury decide its MUSA claim because GIUL sought to rescind its investment in Shenghuo as the remedy for the alleged MUSA violation, this statutory remedy is analogous to cases within the Superior Court’s equity jurisdiction as to which there is no constitutional right to a trial, and MUSA does not create any statutory right to a jury trial. See Bertolino v. Fracassa, Suffolk Super. Ct. no. 1784CV00210-BLS2, 2020 WL 8183088, at *1 (Oct. 27. 2020) (Sanders, J.); see generally Rosati v. Boston Pipe Covering, Inc., 434 Mass. 349, 350 (2001) (if plaintiff’s claim “ ’is analogous, in either subject matter or remedy sought, to cases within the court’s equity jurisdiction, as it existed at the time of the adoption of the Constitution,’ there is no right to trial by jury”) (quoting Dalis v. Buyer Advertising, Inc., 418 Mass. 220, 223 (1994)); see also Demoulas v. Demoulas Super Markets, Inc., 424 Mass. 501, 526–527 (1997) (no right to jury trial on shareholder derivative claim for rescission); Ginn v. Almy, 212 Mass. 486, 494–495 (1912) (no right to jury trial on claim for rescission of transfer of money or stock); Keville v. McKeever, 42 Mass. App. Ct. 140, 147 (1997) (no right to jury trial on claim for rescission of transfers of real and personal property).

There is similarly no constitutional or statutory right to a trial by jury on a claim under G.L. c. 93A. See Nei v. Burley, 388 Mass. 307, 315 (1983).

2. Findings of Fact. The Court heard testimony from five witnesses, and admitted 47 exhibits into evidence, during a four-day bench trial. The witnesses were Paul Conte, who owns and controls GIUL, and the four individual defendants. The Court makes the following findings of fact based on the testimony and exhibits presented at trial, and on reasonable inferences that the Court has drawn from that evidence. The Court does not credit any trial testimony, by Mr. Conte or the individual defendants, that is inconsistent with its findings below.

liability in tort’ ”) quoting Aetna Cas. Sur. Co. v. P & B Autobody, 43 F.3d 1546, 1564 (1st Cir. 1994); Bartle v. Berry, 80 Mass. App. Ct.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bryant v. Avado Brands, Inc.
187 F.3d 1271 (Eleventh Circuit, 1999)
Insurance Co. v. Dutcher
95 U.S. 269 (Supreme Court, 1877)
Pinter v. Dahl
486 U.S. 622 (Supreme Court, 1988)
Lustgraaf v. Behrens
619 F.3d 867 (Eighth Circuit, 2010)
Shaw v. Digital Equipment Corp.
82 F.3d 1194 (First Circuit, 1996)
Aldridge v. A.T. Cross Corp.
284 F.3d 72 (First Circuit, 2002)
In Re Lehman Bros. Mortgage-Backed Securities
650 F.3d 167 (Second Circuit, 2011)
Paul Bennett v. Hunter Durham
683 F.3d 734 (Sixth Circuit, 2012)
Ward v. Bullis
2008 ND 80 (North Dakota Supreme Court, 2008)
J & R MARKETING, SEP v. General Motors Corp.
549 F.3d 384 (Sixth Circuit, 2008)
Atlanta Skin & Cancer Clinic, P.C. v. Hallmark General Partners, Inc.
463 S.E.2d 600 (Supreme Court of South Carolina, 1995)
Baker, Watts & Co. v. Miles & Stockbridge
620 A.2d 356 (Court of Special Appeals of Maryland, 1993)
Nei v. Burley
446 N.E.2d 674 (Massachusetts Supreme Judicial Court, 1983)
Polaroid Corp. v. Rollins Environmental Services (NJ), Inc.
624 N.E.2d 959 (Massachusetts Supreme Judicial Court, 1993)
McCartin v. Westlake
630 N.E.2d 283 (Massachusetts Appeals Court, 1994)
Galotti v. United States Trust Co.
140 N.E.2d 449 (Massachusetts Supreme Judicial Court, 1957)
Holmes Realty Trust v. Granite City Storage Co.
517 N.E.2d 502 (Massachusetts Appeals Court, 1988)
CFT Seaside Investment Ltd. Partnership v. Hammet
868 F. Supp. 836 (D. South Carolina, 1994)

Cite This Page — Counsel Stack

Bluebook (online)
Giul, LLC v. Shenghuo Medical, LLC, D/B/A K2 Medical; Michael J. Antonoplos, Richard P. Blumberg, Mark L. Faupel, and Mark S. Pearlstein, Counsel Stack Legal Research, https://law.counselstack.com/opinion/giul-llc-v-shenghuo-medical-llc-dba-k2-medical-michael-j-mass-2024.